This study analyzed a cohort of 1,254 patients with biliary tract cancer to assess the utility of targeted NGS molecular profiling. It revealed that 59% of patients harbored at least one OncoKB alteration, and 32.2% had level 1/2 alterations, with varying frequencies across tumor locations. Targeted therapies were associated with improved progression-free survival but not overall survival. The study also identified co-occurring alterations and acquired resistance mechanisms, such as ERBB2 loss or alterations in the RAS, MEK, MET, MYC, and CDKN2A pathways. These findings highlight genomic heterogeneity and the importance of precision medicine in informing future drug development efforts.
This study conducted deep multi-omic analyses on over 300 lung neuroendocrine tumours (NETs) and supra-carcinoids, integrating whole-genome sequencing, transcriptome profiling, and DNA methylation arrays. Researchers identified four strikingly different molecular groups, varying in patient characteristics, genomic and transcriptomic profiles, microenvironment, and morphology. A new molecular group, enriched for highly aggressive supra-carcinoids with an immune-rich microenvironment linked to tumor-macrophage crosstalk, was discovered. This morpho-molecular classification unifies previous proposals and offers potential implications for prognosis and therapeutic management, particularly through the identification of group-specific therapeutic targets such as DLL3, EGFR, FGFR, and TERT.